Overview

Full Product Details

Author:   K Schneider
Publisher:   John Wiley and Sons Ltd
Imprint:   Wiley-Blackwell
Edition:   3rd Edition
Dimensions:   Width: 15.50cm , Height: 2.40cm , Length: 23.60cm
Weight:   0.838kg
ISBN:  

9780470081501

ISBN 10:   0470081503
Pages:   496
Publication Date:   12 June 2012
Audience:   Professional and scholarly ,  Professional & Vocational
Replaced By:   9781119466468
Format:   Paperback
Publisher's Status:   Unknown
Availability:   Awaiting stock  

Table of Contents

FOREWORD, XI PREFACE, XIII ACKNOWLEDGMENTS, XV CHAPTER 1: CANCER EPIDEMIOLOGY, 1 1.1. CANCER STATISTICS, 1 1.2. CANCER ETIOLOGY, 10 1.3. CASE EXAMPLES, 18 1.4. FURTHER READING, 21 CHAPTER 2: CANCER DETECTION AND TREATMENT, 23 2.1. THE DIAGNOSIS OF CANCER, 23 2.2. TUMOR CLASSIFICATION, 31 2.3. CANCER TREATMENT, 37 2.4. FURTHER READING, 45 CHAPTER 3: CANCER BIOLOGY, 47 3.1. THE MALIGNANT CELL, 47 3.2. CARCINOGENESIS 52 3.3. ONCOGENES, 59 3.4. TUMOR SUPPRESSOR GENES, 64 3.5. EPIGENETIC MECHANISMS, 70 3.6. FURTHER READING, 73 CHAPTER 4: HEREDITARY CANCER SYNDROMES, 75 4.1. ATAXIA TELANGIECTASIA, 75 4.2. AUTOIMMUNE LYMPHOPROLIFERATIVE SYNDROME (ALSO CANALE–SMITH SYNDROME), 77 4.3. BECKWITH–WIEDEMANN SYNDROME (ALSO EXOMPHALOS MACROGLOSSIA GIGANTISM [EMG] SYNDROME), 78 4.4. BIRT–HOGG–DUBÉ SYNDROME, 80 4.5. BLOOM SYNDROME, 82 4.6. BLUE RUBBER BLEB NEVUS SYNDROME (ALSO TERMED BEAN SYNDROME), 83 4.7. BREAST–OVARIAN CANCER SYNDROME, HEREDITARY, 84 4.8. CARNEY COMPLEX, TYPES I AND II (INCLUDES NAME SYNDROME AND LAMB SYNDROME), 87 4.9. DIAMOND–BLACKFAN ANEMIA, 89 4.10. FAMILIAL ADENOMATOUS POLYPOSIS (ALSO ATTENUATED FAP,GARDNER’S SYNDROME, TURCOT SYNDROME, AND HEREDITARY DESMOID DISEASE), 90 4.11. FANCONI ANEMIA, 93 4.12. GASTRIC CANCER, HEREDITARY DIFFUSE, 95 4.13. GASTROINTESTINAL STROMAL TUMOR, FAMILIAL (ALSO MULTIPLE GI AUTONOMIC NERVE TUMORS), 97 4.14. JUVENILE POLYPOSIS (INCLUDES HEREDITARY MIXED POLYPOSIS), 98 4.15. LEIOMYOMATOSIS RENAL CELL CANCER, HEREDITARY, 100 4.16. LI–FRAUMENI SYNDROME, 101 4.17. LYNCH SYNDROME (ALSO TERMED HNPCC), 105 4.18. MELANOMA, CUTANEOUS MALIGNANT (INCLUDES FAMILIAL ATYPICAL MOLE-MALIGNANT MELANOMA SYNDROME, DYSPLASTIC NEVUS SYNDROME, AND MELANOMA–ASTROCYTOMA SYNDROME), 109 4.19. MULTIPLE ENDOCRINE NEOPLASIA, TYPE 1 (ALSO WERMER SYNDROME), 111 4.20. MULTIPLE ENDOCRINE NEOPLASIA, TYPE 2 (ALSO SIPPLE SYNDROME, FAMILIAL MEDULLARY THYROID CARCINOMA SYNDROME), 113 4.21. MYH-ASSOCIATED POLYPOSIS, 115 4.22. NEUROBLASTOMA, FAMILIAL, 116 4.23. NEUROFIBROMATOSIS, TYPE 1 (ALSO VON RECKLING HAUSEN DISEASE), 118 4.24. NEUROFIBROMATOSIS, TYPE 2, 119 4.25. NEVOID BASAL CELL CARCINOMA SYNDROME (ALSO GORLIN SYNDROME, BASAL CELL NEVUS SYNDROME), 121 4.26. PARAGANGLIOMA–PHEOCHROMOCYTOMA SYNDROME, HEREDITARY (INCLUDING CARNEY–STRATAKIS SYNDROME), 123 4.27. PEUTZ-JEGHERS SYNDROME, 125 4.28. PTEN HAMARTOMA SYNDROME (PHS) (ALSO COWDEN SYNDROME; INCLUDES BANNAYAN–RILEY–RUVALCABA SYNDROME AND PROTEUS SYNDROME), 127 4.29. RENAL CELL CARCINOMA, HEREDITARY PAPILLARY, 130 4.30. RETINOBLASTOMA, HEREDITARY, 131 4.31. ROTHMUND–THOMSON SYNDROME, 133 4.32. TUBEROUS SCLEROSIS COMPLEX (TSC), 134 4.33. VON HIPPEL LINDAU SYNDROME, 137 4.34. WERNER SYNDROME (ALSO TERMED PROGERIA OF THE ADULT), 139 4.35. WILMS TUMOR, FAMILIAL (INCLUDES DENYS-DRASH SYNDROME, FRASIER SYNDROME, WAGR SYNDROME), 141 4.36. XERODERMA PIGMENTOSUM (INCLUDES XP/CS COMPLEX, XP VARIANT), 143 4.37. FURTHER READING, 145 CHAPTER 5: ALL ABOUT BREAST CANCER, 151 5.1. OVERVIEW OF BREAST CANCER, 151 5.2. BREAST CANCER MANAGEMENT: SCREENING, DIAGNOSIS, AND TREATMENT, 162 5.3. BREAST CANCER SYNDROMES, 171 5.4. FURTHER READING, 184 CHAPTER 6: ALL ABOUT COLORECTAL CANCER, 187 6.1. OVERVIEW OF COLORECTAL CANCER, 187 6.2. CRC MANAGEMENT: SCREENING, DIAGNOSIS, AND TREATMENT, 199 6.3. CRC SYNDROMES, 207 6.4. FURTHER READING, 218 CHAPTER 7: COLLECTING AND INTERPRETING CANCER HISTORIES, 221 7.1. COLLECTING A CANCER HISTORY, 221 7.2. CHALLENGES TO COLLECTING AN ACCURATE HISTORY, 242 7.3. INTERPRETING A CANCER HISTORY, 246 7.4. CASE EXAMPLES, 255 7.5. FURTHER READING, 266 CHAPTER 8: CANCER RISK COMMUNICATION, 267 8.1. GENETIC COUNSELING AND RISK PERCEPTION, 267 8.2. THE COMMUNICATION OF RISK, 278 8.3. COUNSELING CLIENTS AT VARIOUS RISKS, 289 8.4. CASE EXAMPLES, 298 8.5. FURTHER READING, 306 CHAPTER 9: GENETIC TESTING AND COUNSELING, 309 9.1. THE LOGISTICS OF ARRANGING TESTS, 309 9.2. PRETEST COUNSELING, 325 9.3. RESULTS DISCLOSURE AND FOLLOW-UP, 337 9.4. CASE EXAMPLES, 346 9.5. FURTHER READING, 356 CHAPTER 10: PSYCHOSOCIAL ASPECTS OF CANCER COUNSELING, 357 10.1. THE PSYCHOSOCIAL FEATURES OF CLIENTS, 357 10.2. MAKING A PSYCHOSOCIAL ASSESSMENT, 379 10.3. PROVIDING ADDITIONAL EMOTIONAL SUPPORT, 394 10.4. CASE EXAMPLES, 400 10.5. FURTHER READING, 407 CHAPTER 11: ETHICAL ISSUES IN CANCER GENETIC COUNSELING, 409 11.1. BIOETHICAL PRINCIPLES AND GUIDELINES, 409 11.2. STRATEGIES FOR RESOLVING ETHICAL DILEMMAS, 423 11.3. TYPES OF ETHICAL DILEMMAS IN CANCER GENETIC COUNSELING, 431 11.4. ISSUES OF JUSTICE, 442 11.5. FURTHER READING, 443 APPENDIX A: SPECIFIC TUMOR TYPES AND ASSOCIATED SYNDROMES, 445 APPENDIX B: REVIEW OF BASIC PEDIGREE SYMBOLS, 457 INDEX, 459

Reviews

Author Information

Katherine Schneider received her Master's Degree in Public Health from Yale University School of Medicine in 1986 and was certified as a genetic counselor by the American Board of Medical Genetics in 1987. She has almost 20 years' experience as a genetic counselor and has been a cancer genetic counselor for the past 13 years. She is currently the Senior Genetic Counselor at the Dana-Farber Cancer Institute in Boston, MA, which has active high risk clinics and predictive testing programs.

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions